Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 15;12(6):1575. doi: 10.3390/cancers12061575

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

In vivo therapeutic efficacy of ABN401 in MET-addicted cancer cell xenograft and c-MET aberrant PDX models. ABN401 suppresses tumor growth in MET-addicted (A) SNU5, (B) EBC-1, and (C) SNU638 cell line xenografts, high MET copy numbers or c-MET IHC3+ and MET exon 14 skipping mutation (D) GA3121, (E) LI0612, (F) LU2503, and (G) LU5381 PDX models, but not in moderate MET copy number (H) GA2278, (I) GA0075, (J) GA0152, and (K) GA0046 PDX models. ABN401 was administered five consecutive days a week for three weeks. For measurement of the tumor growth inhibition index, tumor volumes were measured for three weeks (19 or 22 days) and the results were shown as the mean ± SEM. Comparisons between the vehicle and treatment groups were performed using the t-test. * p < 0.05, ** p < 0.01, *** p < 0.001.

In vivo therapeutic efficacy of ABN401 in MET-addicted cancer cell xenograft and c-MET aberrant PDX models. ABN401 suppresses tumor growth in MET-addicted (A) SNU5, (B) EBC-1, and (C) SNU638 cell line xenografts, high MET copy numbers or c-MET IHC3+ and MET exon 14 skipping mutation (D) GA3121, (E) LI0612, (F) LU2503, and (G) LU5381 PDX models, but not in moderate MET copy number (H) GA2278, (I) GA0075, (J) GA0152, and (K) GA0046 PDX models. ABN401 was administered five consecutive days a week for three weeks. For measurement of the tumor growth inhibition index, tumor volumes were measured for three weeks (19 or 22 days) and the results were shown as the mean ± SEM. Comparisons between the vehicle and treatment groups were performed using the t-test. * p < 0.05, ** p < 0.01, *** p < 0.001.